Related Experiment Video

Updated: Jun 22, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and

Roy Eldor1, Itamar Raz

  • 1Diabetes Research Center, Department of Medicine, Hadassah-Hebrew University Hospital, Jerusalem 91120, Israel.

The Review of Diabetic Studies : RDS
|June 27, 2009
PubMed

Insights

Individualized glycemic control targets and drug selection are crucial for managing diabetes, especially concerning cardiovascular health. Tailoring treatment reduces risks and improves outcomes for diverse patient groups.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Disease Research
  • Diabetes Mellitus Management

Background:

  • Improved glycemic control demonstrably reduces microvascular complications in diabetes.
  • Evidence remains inconclusive regarding the impact of glycemic control on macrovascular disease, including cardiovascular outcomes.
  • Recent large trials (ACCORD, ADVANCE, VADT, UKPDS-80) yielded conflicting results on intensive glycemic control and macrovascular events.

Purpose of the Study:

  • To critically evaluate the methodologies of recent large diabetes trials.
  • To propose an individualized approach for setting glycemic control targets (HbA1c).
  • To suggest a framework for selecting hypoglycemic agents based on multiple patient-specific factors.

Main Methods:

  • Analysis of trial designs, focusing on patient populations and potential biases.
  • Development of a patient-centered method for determining individualized HbA1c targets.
  • Creation of a scoring system to compare and select hypoglycemic drugs based on efficacy and safety profiles.

Main Results:

  • Inadequacies in trial structures (e.g., elderly patients with pre-existing complications) may explain unfavorable outcomes in ACCORD, ADVANCE, and VADT.
  • The UKPDS-80 follow-up indicated benefits of intensive glycemic control initiated in newly diagnosed patients.
  • An individualized HbA1c target considers potential benefits, hypoglycemia risk, and consequences.

Conclusions:

  • A tailored HbA1c goal is essential, differing for young, newly diagnosed patients versus elderly patients with comorbidities.
  • Drug selection should extend beyond glycemic control to include weight effects, durability, cardiovascular protection, and side effect profiles.
  • An individualized treatment strategy, combining tailored HbA1c goals and appropriate drug selection, optimizes patient care in diabetes management.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...